10-Q quarterly report · filed Nov 5, 2026

LB PHARMACEUTICALS INC (LBRX) Q3 2026 10-Q Quarterly Report

Short answer

LB PHARMACEUTICALS INC (LBRX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$59M
−330.1% YoY · −14.5% QoQ
EPS (diluted)
−$1.83
+70.8% YoY · −4.6% QoQ

Source: XBRL data from the LB PHARMACEUTICALS INC (LBRX) Q3 2026 10-Q on SEC EDGAR. USD.

LB PHARMACEUTICALS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales
  • Net loss $59.1M vs $3.6M YoY, operating loss $62.5M vs $5.2M
  • R&D highest spending area: $51.5M, up from $2.4M, driven by schizophrenia trials
  • Cash, equivalents and short-term investments $403.8M at September 30, 2026
  • Operating cash use $125.2M, financing provided $234.7M, investments used $144.6M
  • Outlook: continued losses, cash runway beyond Q2 2029, clinical development and expenses rising significantly

Risk Factors

  • Newly added AI risk: EU AI Act exposure, with noncompliance fines up to €35 million or 7% of worldwide annual turnover
  • Most material update, financial reporting: Unremediated internal-control weaknesses, with remediation targeted by December 31, 2026
  • Regulatory risk: FDA may reject Phase 2 acute-schizophrenia data as one of two pivotal NDA trials
  • Operational risk: Clinical-trial enrollment delays or withdrawals could compromise data quality and extend development timelines
  • Liquidity risk: $403.8 million in cash, equivalents and short-term investments funds operations for at least 12 months, but additional capital remains required

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other LB PHARMACEUTICALS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.